AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$11.02 -0.28%

-$0.02 today

Market cap
$3.60B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.58M

Average 6.37M

ABCL Sales of Investments

Cash received from selling or redeeming investments.

AbCellera Biologics Inc.NASDAQ: ABCL

Sales of Investments · Q3 FY2026 · quarter ended Sep 2026

Sales of investments growth accelerates

Q3 FY2026 sales of investments of $135.61M rose 63.2% year over year, ahead of the -57.5% change in trailing-twelve-month sales of investments. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Sales of investments amounted to 673.6% of revenue in FY2025, down 2617.1 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +63.2% holds above the trailing-twelve-month pace of -57.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$135.61M+194.3% QoQ
Last fiscal yearDec 2025
$506.07M-46.7% YoY
LTMSep 2026
$249.02M-57.5% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+63.2%——
1 year-46.7%——
3-year CAGR-0.3%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
506.07M USD
Year-over-year change
-46.7%
4-year CAGR
+106.9%

Sales of Investments vs competitors

How ABCL compares with its peers on the latest reported figures

  • ABCL's LTM Sep 2026 sales of investments of $249.02M is the 3rd largest of the 4 companies compared; the peer median is $285.01M.
  • Its year-over-year change of -57.5% is the lowest of 4, against a peer median of +24.6%.
  • Sales of investments amounts to 367.0% of revenue for ABCL, versus a peer median of 893.7%.
ABCL Competitors Peer median
Sales of Investments for ABCL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$367.16M +8024.8%—259.8%
GENBGenerate Biomedicines, Inc.FY2025$285.01M +24.6%—893.7%
ABCLAbCellera Biologics Inc.LTM Sep 2026$249.02M -57.5%-0.3%367.0%
ABSIAbsci CorporationLTM Mar 2026$70.5M -52.5%+140.4%3839.9%
Peer median (excluding ABCL) $285.01M+24.6%+140.4%893.7%

Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income153.46M158.52M(146.4M)(162.86M)(146.41M)
Depreciation & Amortization17.25M33.1M30.89M97M28.82M
Deferred Income Tax(2.02M)(2.11M)1.96M00
Stock-Based Compensation30.65M49.48M64.18M67.58M55.79M
Change in Working Capital41.67M29.83M13.23M(25.84M)(70.69M)
Accounts Receivables22.48M(22.72M)(45.93M)(75.12M)(55.62M)
Inventory0018.25M00
Accounts Payables1.4M1.07M(15.1M)10.64M3.46M
Other Working Capital17.79M51.47M56.01M38.64M(18.53M)
Other Non-Cash Items3.57M8.55M(7.74M)(84.44M)1.2M
Operating Cash Flow244.58M277.36M(43.88M)(108.56M)(131.3M)
Capital Expenditures(58.45M)(72.66M)(77.51M)(78.4M)(42.77M)
Acquisitions (Net)(11.46M)(25.68M)(13.69M)(19.63M)(7.14M)
Purchases of Investments(322.57M)(781.35M)(1.07B)(765.09M)(453.14M)
Sales of Investments27.61M510.63M910.94M948.81M506.07M
Other Investing Activities32.62M16.43M25.31M35.71M84.72M
Investing Cash Flow(332.25M)(352.63M)(221.11M)121.41M87.75M
Debt Repayment(951K)2.76M11.59M13.5M0
Common Stock Issued4.62M0000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(7.55M)(4.38M)(1.23M)(729K)14.08M
Financing Cash Flow(3.89M)(1.63M)10.36M12.77M14.08M
Effect of Forex Changes(1.43M)(9.6M)589K(2.62M)1.1M
Net Change in Cash(92.97M)(86.49M)(254.04M)23.01M(28.37M)
Free Cash Flow186.13M204.7M(121.38M)(186.95M)(174.07M)

AbCellera Biologics Inc.

NASDAQ:ABCL

Intrinsic Alpha fair value

Locked

Current Price

$11.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.